Table 1.

Summary of Recommendations

Population	Pages	Recommended Screening Method**	Management of Screen Results	Comments
< 21 Years	xx-yy	No Screening		HPV testing should NOT be used for screening or triage of ASC-US in this age group.
21–29 Years	xx-yy	Cytology alone every 3 years	HPV-Positive ASC-US or cytology of LSIL or more severe: Refer to ASCCP Guidelines2	HPV testing should NOT be used for screening in this age group
			Cytology Negative or HPV-Negative ASC-US*: Rescreen with cytology in 3 years
30–65 Years	xx-yy	HPV and Cytology “Cotesting” every 5 years (Preferred)	HPV-Positive ASC-US or cytology of LSIL or more severe: Refer to ASCCP Guidelines2	Screening by HPV testing alone is not recommended for most clinical settings.
			HPV Positive, Cytology Negative: Option 1 -- 12-month follow-up with cotesting Option 2 -- Test for HPV16 or HPV16/18 Genotyping if HPV16 or HPV16/18 positive: refer to colposcopy If HPV16 or HPV16/18 negative: 12-month follow-up with cotesting
			Cotest Negative or HPV-Negative ASC-US: Rescreen with cotesting in 5 years
		Cytology alone every 3 years (Acceptable)	HPV-Positive ASC-US* or cytology of LSIL or more severe: Refer to ASCCP Guidelines 2
			Cytology Negative or HPV-Negative ASC-US*: Rescreen with cytology in 3 years
>65 Years	xx-yy	No Screening following adequate negative prior screening		Women with a history of CIN2 or a more severe diagnosis should continue routine screening for at least 20 years.
After Hysterectomy	xx-yy	No Screening		Applies to women without a cervix and without a history of CIN2 or a more severe diagnosis in the past 20 years or cervical cancer ever.
HPV Vaccinated	xx-yy	Follow age-specific recommendations (no changes)

^*ASC-US cytology with secondary HPV testing for management decisions

^**Women should not be screened annually at any age by any method